Skip to main content

Part of the book series: ISGE Series ((ISGE))

  • 548 Accesses

Abstract

As well known, infertility is a prevalent presenting feature of PCOS with ~75% of these women suffering infertility due to anovulation, making PCOS the most common cause of anovulatory infertility. Women with PCOS often have many concerns about childbearing including whether they could become pregnant and what they should do before they try to become pregnant. Polycystic ovary syndrome (PCOS) is a common female reproductive endocrine disease. The prevalence in premenopausal women ranges from 6 to 20%, possibly making this syndrome as the most common endocrine and metabolic disorder in women of reproductive age [1–3]. According to the reports in specialized departments of China like in our “Department of Gynecological Endocrinology,” it stands as the most important disease – in our daily clinic from more than 500 outpatients, at least 50% are diagnosed with PCOS, and more than 50,000 per year of our PCOS patients get treatment as described in this chapter. The disease can begin in early adolescence, the etiology is not yet clear, the pathogenesis is complex, and it is related to environmental (especially nutrition) factors. Particularly, genetical factors may also play an important role in the development of the disease and differences in type and outcome [4]. Changes of endocrine and metabolic markers are often associated with PCOS although are not decisive for the diagnosis. In 2003, the “European Society for Human Reproduction and Embryology (ESHRE)” and the “American Society of Reproductive Medicine (ASRM)” revised the diagnostic criteria for PCOS at the Rotterdam meeting [5]: (1) rare ovulation or anovulation; (2) abnormal clinical manifestations and/or biochemical indicators of hyperandrogenism; and (3) polycystic ovarian morphology (PCOM): follicle number of 2–9 mm in diameter in one or both ovaries ≥12 and/or ovarian volume >10 cm3. In 2018 the cut-off for follicle number was raised to 20 or more in either ovary [2]. If at least two of the three abovementioned criteria are met, “PCOS” can be diagnosed, whereby diseases such as thyroid dysfunction, Cushing’s syndrome, androgen-secreting tumors, hyper-prolactinemia, pituitary gland diseases, and premature ovarian failure must be excluded.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 99.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol. 2018;14:270–84.

    Article  PubMed  Google Scholar 

  2. Teede HJ, Misso ML, Costello MF, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018;33:1602–18.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Chen Z, Tian Q, Qiao J, et al. Guidelines for the diagnosis and treatment of polycystic ovary syndrome in China. Chinese J Obst Gynecol. 2018;53(1):2–6.

    Google Scholar 

  4. Conway G, Dewailly D, Diamanti-Kandarakis E, et al. The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. Eur J Endocrinol. 2014;171:P1–29.

    Article  CAS  PubMed  Google Scholar 

  5. EA-SPcwg R (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81:19–25.

    Google Scholar 

  6. Tian X, Ruan X, Mueck AO, et al. Anti-Mullerian hormone levels in women with polycystic ovarian syndrome compared with normal women of reproductive age in China. Gynecol Endocrinol. 2014;30:126–9.

    Article  CAS  PubMed  Google Scholar 

  7. Tian X, Ruan X, Mueck AO, et al. Serum anti-Mullerian hormone and insulin resistance in the main phenotypes of non-obese polycystic ovarian syndrome women in China. Gynecol Endocrinol. 2014;30:836–9.

    Article  CAS  PubMed  Google Scholar 

  8. Jin J, Ruan X, Hua L, et al. Prevalence of diminished ovarian reserve in Chinese women with polycystic ovary syndrome and sensitive diagnostic parameters. Gynecol Endocrinol. 2017;33:694–7.

    Article  PubMed  Google Scholar 

  9. Cassar S, Teede HJ, Moran LJ, et al. Polycystic ovary syndrome and anti-Mullerian hormone: role of insulin resistance, androgens, obesity and gonadotrophins. Clin Endocrinol. 2014;81:899–906.

    Article  CAS  Google Scholar 

  10. Ruan X, Kubba A, Aguilar A, et al. Use of cyproterone acetate/ethinylestradiol in polycystic ovary syndrome: rationale and practical aspects. Eur J Contracept Reprod Health Care. 2017;22(3):183–90.

    Article  CAS  PubMed  Google Scholar 

  11. Sirmans SM, Pate KA. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol. 2014;6:1–13.

    Google Scholar 

  12. Fauser BCJM, Tarlatzis BC, Rebar RW, et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-sponsored 3rd PCOS consensus workshop group. Fertil Steril. 2012;97:28–38.

    Article  PubMed  Google Scholar 

  13. Badawy AS, Elnashar A. Treatment options for polycystic ovary syndrome. Int J Women's Health. 2011;3:25–35.

    Article  Google Scholar 

  14. Poretsky L, Piper B. Insulin resistance, hypersensitivity of LH, and dual defect hypothesis for the pathogenesis of polycystic ovary syndrome. Obstet Gynecol. 1994;84:613–21.

    CAS  PubMed  Google Scholar 

  15. McCartney CR, Eagleson CR, Marshall JC. Regulation of gonadotropin secretion: implications for polycystic ovary syndrome. Semin Reprod Med. 2002;20:317–36.

    Article  CAS  PubMed  Google Scholar 

  16. Lizneva D, Suturina L, Walker W, et al. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016;106:6–15.

    Article  PubMed  Google Scholar 

  17. Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012;33:981–1030.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Norman RJ, Dewailly D, Legro RS, et al. Polycystic ovary syndrome. Lancet. 2007;370:685–97.

    Article  CAS  PubMed  Google Scholar 

  19. Ruan X, Mueck AO. Oral contraception for women of middle age. Maturitas. 2015;82:266–70.

    Article  CAS  PubMed  Google Scholar 

  20. Lim SS, Davies MJ, Norman RJ, et al. Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2012;18:618–37.

    Article  CAS  PubMed  Google Scholar 

  21. Dumesic DA, Akopians AL, Madrigal VK, et al. Hyperandrogenism accompanies increased intra-abdominal fat storage in Normal weight polycystic ovary syndrome women. J Clin Endocrinol Metab. 2016;101:4178–88.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Arpaci D, Gurkan Tocoglu A, et al. The relationship between epicardial fat tissue thickness and visceral adipose tissue in lean patients with polycystic ovary syndrome. J Ovarian Res. 2015;8:71.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  23. Ollila MM, West S, Keinanen-Kiukaaniemi S, et al. Overweight and obese but not normal weight women with PCOS are at increased risk of type 2 diabetes mellitus-a prospective population-based cohort study. Hum Reprod. 2017;32:968.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Delitala AP, Capobianco G, Delitala G, et al. Polycystic ovary syndrome, adipose tissue and metabolic syndrome. Arch Gynecol Obstet. 2017;296:405–19.

    Article  CAS  PubMed  Google Scholar 

  25. Legro RS, Dodson WC, Kunselman AR, et al. Benefit of delayed fertility therapy with preconception weight loss over immediate therapy in obese women with PCOS. J Clin Endocrinol Metab. 2016;101:2658–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Zhao Y, Ruan X, Mueck AO. Letrozole combined with low dose highly purified HMG for ovulation induction in clomiphene citrate-resistant infertile Chinese women with polycystic ovary syndrome: a prospective study. Gynecol Endocrinol. 2017;33:462–6.

    Article  CAS  PubMed  Google Scholar 

  27. Legro RS, Dodson WC, Kris-Etherton PM, et al. Randomized controlled trial of preconception interventions in infertile women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2015;100:4048–58.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Wu H, Ruan X, Jin J, et al. Metabolic profile of Diane-35 versus Diane-35 plus metformin in Chinese PCOS women under standardized life-style changes. Gynecol Endocrinol. 2015;31:548–51.

    Article  CAS  PubMed  Google Scholar 

  29. Dokras A, Sarwer DB, Allison KC, et al. Weight loss and lowering androgens predict improvements in health-related quality of life in women with PCOS. J Clin Endocrinol Metab. 2016;101:2966–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Riley JK, Jungheim ES. Is there a role for diet in ameliorating the reproductive sequelae associated with chronic low-grade inflammation in polycystic ovary syndrome and obesity? Fertil Steril. 2016;106:520–7.

    Article  PubMed  Google Scholar 

  31. McKinnon CJ, Hatch EE, Rothman KJ, et al. Body mass index, physical activity and fecundability in a north American preconception cohort study. Fertil Steril. 2016;106:451–9.

    Article  PubMed  Google Scholar 

  32. Song J, Ruan X, Gu M, et al. Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance. Gynecol Endocrinol. 2018;34:413–7.

    Article  CAS  PubMed  Google Scholar 

  33. Ruan X, Song J, Gu M, et al. Effect of Diane-35, alone or in combination with orlistat or metformin in Chinese polycystic ovary syndrome patients. Arch Gynecol Obstet. 2018;297:1557–63.

    Article  CAS  PubMed  Google Scholar 

  34. Escobar-Morreale HF, Santacruz E, Luque-Ramirez M, et al. Prevalence of 'obesity-associated gonadal dysfunction' in severely obese men and women and its resolution after bariatric surgery: a systematic review and meta-analysis. Hum Reprod Update. 2017;23:390–408.

    Article  CAS  PubMed  Google Scholar 

  35. Lo JC, Feigenbaum SL, Yang J, et al. Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91:1357–63.

    Article  CAS  PubMed  Google Scholar 

  36. Cassar S, Misso ML, Hopkins WG, et al. Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic-hyperinsulinaemic clamp studies. Hum Reprod. 2016;31:2619–31.

    Article  CAS  PubMed  Google Scholar 

  37. Benham JL, Yamamoto JM, Friedenreich CM, et al. Role of exercise training in polycystic ovary syndrome: a systematic review and meta-analysis. Clin Obes. 2018;8:275–84.

    Article  CAS  PubMed  Google Scholar 

  38. American Diabetes Association. Management of diabetes in pregnancy. Diabetes Care. 2017;40(Suppl 1):S114–9.

    Google Scholar 

  39. Anagnostis P, Tarlatzis BC, Kauffman RP. Polycystic ovarian syndrome (PCOS): long-term metabolic consequences. Metabolism. 2018;86:33–43.

    Article  CAS  PubMed  Google Scholar 

  40. Katulski K, Czyzyk A, Podfigurna-Stopa A, et al. Pregnancy complications in polycystic ovary syndrome patients. Gynecol Endocrinol. 2015;31:87–91.

    Article  PubMed  Google Scholar 

  41. Qin JZ, Pang LH, Li MJ, et al. Obstetric complications in women with polycystic ovary syndrome: a systematic review and meta-analysis. Reprod Biol Endocrinol. 2013;11:56.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Naver KV, Grinsted J, Larsen SO, et al. Increased risk of preterm delivery and pre-eclampsia in women with polycystic ovary syndrome and hyperandrogenaemia. BJOG. 2014;121:575–81.

    Article  CAS  PubMed  Google Scholar 

  43. Li Y, Ruan X, Wang H, et al. Comparing the risk of adverse pregnancy outcomes of Chinese patients with polycystic ovary syndrome with and without antiandrogenic pretreatment. Fertil Steril. 2018;109:720–7.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

Supported by Beijing Municipal Administration of Hospitals’ Ascent Plan (DFL20181401), Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support (XMLX201710).

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2021 International Society of Gynecological Endocrinology

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Ruan, X., Mueck, A.O. (2021). Management of PCOS Women Preparing Pregnancy. In: Genazzani, A.R., Ibáñez, L., Milewicz, A., Shah, D. (eds) Impact of Polycystic Ovary, Metabolic Syndrome and Obesity on Women Health. ISGE Series. Springer, Cham. https://doi.org/10.1007/978-3-030-63650-0_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-63650-0_11

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-63649-4

  • Online ISBN: 978-3-030-63650-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics